Concepts (195)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Uterine Cervical Neoplasms | 15 | 2025 | 297 | 3.440 |
Why?
|
| Ovarian Neoplasms | 8 | 2024 | 595 | 1.640 |
Why?
|
| Cystadenocarcinoma, Serous | 4 | 2024 | 32 | 1.310 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 7 | 2025 | 411 | 1.170 |
Why?
|
| Hysterectomy | 9 | 2025 | 85 | 1.110 |
Why?
|
| Uterine Neoplasms | 3 | 2017 | 71 | 0.960 |
Why?
|
| Neoplasm Recurrence, Local | 6 | 2024 | 330 | 0.920 |
Why?
|
| Genital Neoplasms, Female | 2 | 2018 | 67 | 0.920 |
Why?
|
| Endometrial Neoplasms | 6 | 2024 | 189 | 0.900 |
Why?
|
| Chemoradiotherapy | 5 | 2025 | 44 | 0.900 |
Why?
|
| Cisplatin | 4 | 2025 | 179 | 0.870 |
Why?
|
| Neoplasm Staging | 13 | 2025 | 478 | 0.850 |
Why?
|
| Prealbumin | 1 | 2022 | 4 | 0.810 |
Why?
|
| Female | 37 | 2025 | 15156 | 0.810 |
Why?
|
| Middle Aged | 26 | 2025 | 7164 | 0.770 |
Why?
|
| Aged | 18 | 2025 | 5416 | 0.630 |
Why?
|
| Salpingectomy | 3 | 2018 | 8 | 0.620 |
Why?
|
| Adult | 23 | 2025 | 7757 | 0.610 |
Why?
|
| Ovariectomy | 3 | 2018 | 53 | 0.610 |
Why?
|
| United States Indian Health Service | 1 | 2018 | 14 | 0.580 |
Why?
|
| Patient Navigation | 1 | 2018 | 7 | 0.580 |
Why?
|
| Humans | 37 | 2025 | 28121 | 0.580 |
Why?
|
| Sentinel Lymph Node Biopsy | 2 | 2014 | 17 | 0.530 |
Why?
|
| Retrospective Studies | 9 | 2022 | 2557 | 0.520 |
Why?
|
| Immunotherapy | 1 | 2018 | 158 | 0.510 |
Why?
|
| Topotecan | 1 | 2015 | 12 | 0.500 |
Why?
|
| Status Epilepticus | 1 | 2015 | 5 | 0.490 |
Why?
|
| Leiomyoma | 2 | 2014 | 9 | 0.460 |
Why?
|
| Aged, 80 and over | 8 | 2024 | 2021 | 0.460 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2025 | 144 | 0.430 |
Why?
|
| Indians, North American | 1 | 2018 | 517 | 0.420 |
Why?
|
| Lymph Nodes | 1 | 2014 | 103 | 0.420 |
Why?
|
| Attitude to Health | 1 | 2014 | 89 | 0.420 |
Why?
|
| Quality of Life | 3 | 2025 | 491 | 0.410 |
Why?
|
| Perception | 1 | 2013 | 89 | 0.410 |
Why?
|
| Carcinoma | 1 | 2014 | 75 | 0.410 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2014 | 95 | 0.410 |
Why?
|
| Anxiety | 1 | 2013 | 146 | 0.390 |
Why?
|
| BRCA1 Protein | 2 | 2024 | 24 | 0.370 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2013 | 296 | 0.350 |
Why?
|
| Uterine Artery Embolization | 1 | 2010 | 2 | 0.350 |
Why?
|
| Pelvis | 3 | 2025 | 38 | 0.330 |
Why?
|
| Fertility Preservation | 2 | 2025 | 8 | 0.300 |
Why?
|
| Lymph Node Excision | 5 | 2025 | 100 | 0.300 |
Why?
|
| Survival Analysis | 2 | 2019 | 289 | 0.280 |
Why?
|
| Young Adult | 5 | 2019 | 2731 | 0.280 |
Why?
|
| Paclitaxel | 2 | 2019 | 190 | 0.260 |
Why?
|
| Pyridines | 2 | 2025 | 108 | 0.260 |
Why?
|
| Neoplasms | 2 | 2025 | 818 | 0.250 |
Why?
|
| Telomere-Binding Proteins | 1 | 2025 | 5 | 0.240 |
Why?
|
| Feasibility Studies | 2 | 2025 | 193 | 0.240 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2022 | 114 | 0.240 |
Why?
|
| Germ-Line Mutation | 1 | 2025 | 32 | 0.240 |
Why?
|
| Vaginal Neoplasms | 1 | 2025 | 12 | 0.240 |
Why?
|
| Maintenance Chemotherapy | 1 | 2024 | 17 | 0.230 |
Why?
|
| Postoperative Complications | 3 | 2022 | 613 | 0.230 |
Why?
|
| Neoadjuvant Therapy | 1 | 2025 | 73 | 0.230 |
Why?
|
| Indazoles | 1 | 2024 | 18 | 0.220 |
Why?
|
| Piperidines | 1 | 2024 | 48 | 0.220 |
Why?
|
| Poly(ADP-ribose) Polymerase Inhibitors | 1 | 2024 | 37 | 0.220 |
Why?
|
| Pilot Projects | 2 | 2022 | 432 | 0.210 |
Why?
|
| BRCA2 Protein | 2 | 2024 | 19 | 0.200 |
Why?
|
| Interleukin-8 | 1 | 2022 | 45 | 0.200 |
Why?
|
| Cytoreduction Surgical Procedures | 1 | 2022 | 33 | 0.200 |
Why?
|
| Vitamin D | 1 | 2022 | 49 | 0.200 |
Why?
|
| Surveys and Questionnaires | 4 | 2025 | 969 | 0.190 |
Why?
|
| Nomograms | 1 | 2021 | 9 | 0.180 |
Why?
|
| Interleukin-6 | 1 | 2022 | 193 | 0.180 |
Why?
|
| Medroxyprogesterone Acetate | 1 | 2021 | 18 | 0.180 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2021 | 29 | 0.180 |
Why?
|
| Endometrium | 2 | 2022 | 39 | 0.180 |
Why?
|
| Granulosa Cell Tumor | 1 | 2019 | 3 | 0.160 |
Why?
|
| Ovarian Cysts | 1 | 2019 | 6 | 0.160 |
Why?
|
| Conization | 3 | 2025 | 11 | 0.160 |
Why?
|
| Radiotherapy | 1 | 2019 | 41 | 0.160 |
Why?
|
| Biomarkers | 1 | 2022 | 755 | 0.160 |
Why?
|
| Pituitary Neoplasms | 1 | 2019 | 48 | 0.150 |
Why?
|
| Adenoma | 1 | 2019 | 61 | 0.150 |
Why?
|
| Adenocarcinoma | 2 | 2021 | 297 | 0.140 |
Why?
|
| Patient Compliance | 1 | 2018 | 75 | 0.140 |
Why?
|
| Antibodies, Neutralizing | 2 | 2015 | 72 | 0.140 |
Why?
|
| Adolescent | 4 | 2018 | 3123 | 0.130 |
Why?
|
| Fallopian Tubes | 1 | 2016 | 15 | 0.130 |
Why?
|
| Multivariate Analysis | 1 | 2017 | 300 | 0.130 |
Why?
|
| Combined Modality Therapy | 1 | 2017 | 302 | 0.130 |
Why?
|
| Disease-Free Survival | 3 | 2025 | 238 | 0.130 |
Why?
|
| HIV Antibodies | 1 | 2015 | 2 | 0.120 |
Why?
|
| Risk Factors | 3 | 2021 | 2084 | 0.120 |
Why?
|
| Seizures | 1 | 2015 | 48 | 0.120 |
Why?
|
| HIV-1 | 1 | 2015 | 58 | 0.120 |
Why?
|
| Neoplasm Invasiveness | 3 | 2021 | 190 | 0.120 |
Why?
|
| Prospective Studies | 3 | 2025 | 1249 | 0.120 |
Why?
|
| Uterine Hemorrhage | 1 | 2014 | 9 | 0.120 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2021 | 385 | 0.110 |
Why?
|
| Prognosis | 1 | 2017 | 803 | 0.110 |
Why?
|
| Brachytherapy | 2 | 2025 | 51 | 0.110 |
Why?
|
| Genes, BRCA2 | 1 | 2014 | 10 | 0.110 |
Why?
|
| Genes, BRCA1 | 1 | 2014 | 12 | 0.110 |
Why?
|
| Fellowships and Scholarships | 1 | 2014 | 39 | 0.110 |
Why?
|
| Heterozygote | 1 | 2014 | 65 | 0.110 |
Why?
|
| Premenopause | 1 | 2014 | 20 | 0.110 |
Why?
|
| Gynecology | 1 | 2014 | 58 | 0.110 |
Why?
|
| Antibodies, Monoclonal | 1 | 2015 | 329 | 0.110 |
Why?
|
| Lymphatic Metastasis | 1 | 2014 | 125 | 0.110 |
Why?
|
| HIV Infections | 1 | 2015 | 157 | 0.110 |
Why?
|
| Palliative Care | 1 | 2014 | 82 | 0.100 |
Why?
|
| Treatment Outcome | 3 | 2021 | 2380 | 0.100 |
Why?
|
| Medical Oncology | 1 | 2014 | 94 | 0.100 |
Why?
|
| Laparoscopy | 1 | 2014 | 146 | 0.100 |
Why?
|
| Mental Health | 1 | 2013 | 99 | 0.100 |
Why?
|
| Early Detection of Cancer | 1 | 2013 | 125 | 0.100 |
Why?
|
| Hereditary Breast and Ovarian Cancer Syndrome | 1 | 2012 | 1 | 0.100 |
Why?
|
| Colorectal Neoplasms, Hereditary Nonpolyposis | 1 | 2012 | 5 | 0.100 |
Why?
|
| United States | 1 | 2018 | 2149 | 0.090 |
Why?
|
| Risk | 1 | 2012 | 136 | 0.090 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2025 | 164 | 0.090 |
Why?
|
| Vulvar Neoplasms | 1 | 2011 | 25 | 0.090 |
Why?
|
| Ebola Vaccines | 1 | 2010 | 1 | 0.090 |
Why?
|
| Viral Envelope Proteins | 1 | 2010 | 6 | 0.090 |
Why?
|
| Hemorrhagic Fever, Ebola | 1 | 2010 | 8 | 0.090 |
Why?
|
| Adenoviruses, Human | 1 | 2010 | 22 | 0.090 |
Why?
|
| Neoplasm Grading | 2 | 2024 | 104 | 0.090 |
Why?
|
| Genetic Vectors | 1 | 2010 | 116 | 0.080 |
Why?
|
| Survival Rate | 2 | 2024 | 430 | 0.080 |
Why?
|
| Time Factors | 1 | 2014 | 1593 | 0.080 |
Why?
|
| Pain Measurement | 1 | 2010 | 166 | 0.080 |
Why?
|
| Attitude of Health Personnel | 1 | 2010 | 143 | 0.080 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2010 | 163 | 0.080 |
Why?
|
| Severity of Illness Index | 1 | 2010 | 454 | 0.080 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2012 | 677 | 0.080 |
Why?
|
| Pregnancy | 2 | 2025 | 1181 | 0.070 |
Why?
|
| Double-Blind Method | 2 | 2024 | 414 | 0.070 |
Why?
|
| Risk Assessment | 1 | 2010 | 611 | 0.070 |
Why?
|
| Age Factors | 2 | 2024 | 733 | 0.070 |
Why?
|
| Follow-Up Studies | 1 | 2010 | 1014 | 0.070 |
Why?
|
| Male | 5 | 2025 | 13487 | 0.070 |
Why?
|
| Thiosemicarbazones | 1 | 2025 | 5 | 0.060 |
Why?
|
| Lymphedema | 1 | 2025 | 15 | 0.060 |
Why?
|
| Radiotherapy, Intensity-Modulated | 1 | 2025 | 37 | 0.060 |
Why?
|
| B7-H1 Antigen | 1 | 2025 | 38 | 0.060 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2025 | 77 | 0.060 |
Why?
|
| Homologous Recombination | 1 | 2024 | 10 | 0.060 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2025 | 42 | 0.060 |
Why?
|
| Phthalazines | 1 | 2024 | 22 | 0.060 |
Why?
|
| Marijuana Use | 1 | 2024 | 41 | 0.060 |
Why?
|
| Genetic Testing | 1 | 2024 | 68 | 0.050 |
Why?
|
| Cannabis | 1 | 2024 | 47 | 0.050 |
Why?
|
| Cohort Studies | 1 | 2025 | 886 | 0.050 |
Why?
|
| Estriol | 1 | 2022 | 3 | 0.050 |
Why?
|
| Estrone | 1 | 2022 | 5 | 0.050 |
Why?
|
| Everolimus | 1 | 2022 | 16 | 0.050 |
Why?
|
| Drug Combinations | 1 | 2022 | 50 | 0.050 |
Why?
|
| Cervix Uteri | 1 | 2022 | 64 | 0.050 |
Why?
|
| Bevacizumab | 1 | 2022 | 103 | 0.050 |
Why?
|
| Indoles | 1 | 2022 | 99 | 0.050 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2022 | 136 | 0.050 |
Why?
|
| Estradiol | 1 | 2022 | 175 | 0.040 |
Why?
|
| Benzamides | 1 | 2021 | 34 | 0.040 |
Why?
|
| Time-to-Treatment | 1 | 2021 | 28 | 0.040 |
Why?
|
| Clinical Decision-Making | 1 | 2021 | 63 | 0.040 |
Why?
|
| Proportional Hazards Models | 1 | 2021 | 226 | 0.040 |
Why?
|
| Disease Management | 1 | 2021 | 88 | 0.040 |
Why?
|
| Luteinization | 1 | 2019 | 7 | 0.040 |
Why?
|
| Microsatellite Instability | 1 | 2019 | 10 | 0.040 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2020 | 194 | 0.040 |
Why?
|
| Ovary | 1 | 2019 | 69 | 0.040 |
Why?
|
| DNA Mutational Analysis | 1 | 2019 | 94 | 0.040 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2019 | 110 | 0.040 |
Why?
|
| Diagnosis, Differential | 1 | 2019 | 372 | 0.040 |
Why?
|
| Antineoplastic Agents | 1 | 2024 | 678 | 0.040 |
Why?
|
| Risk Reduction Behavior | 1 | 2018 | 46 | 0.040 |
Why?
|
| Mucous Membrane | 1 | 2016 | 27 | 0.030 |
Why?
|
| Organoplatinum Compounds | 1 | 2016 | 24 | 0.030 |
Why?
|
| Half-Life | 1 | 2015 | 34 | 0.030 |
Why?
|
| Biopsy | 1 | 2016 | 207 | 0.030 |
Why?
|
| Immunohistochemistry | 1 | 2016 | 462 | 0.030 |
Why?
|
| Risk Adjustment | 1 | 2014 | 8 | 0.030 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2016 | 167 | 0.030 |
Why?
|
| Medical Records | 1 | 2014 | 51 | 0.030 |
Why?
|
| Texas | 1 | 2014 | 135 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2015 | 605 | 0.030 |
Why?
|
| Biomarkers, Tumor | 1 | 2016 | 406 | 0.030 |
Why?
|
| Biomedical Research | 1 | 2014 | 97 | 0.030 |
Why?
|
| False Negative Reactions | 1 | 2011 | 24 | 0.020 |
Why?
|
| Vaccines, Attenuated | 1 | 2010 | 7 | 0.020 |
Why?
|
| Ebolavirus | 1 | 2010 | 8 | 0.020 |
Why?
|
| Neutralization Tests | 1 | 2010 | 34 | 0.020 |
Why?
|
| Placebos | 1 | 2010 | 47 | 0.020 |
Why?
|
| Antibodies, Viral | 1 | 2010 | 79 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2010 | 257 | 0.020 |
Why?
|
| Evidence-Based Medicine | 1 | 2011 | 145 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2011 | 521 | 0.020 |
Why?
|
| T-Lymphocytes | 1 | 2010 | 283 | 0.020 |
Why?
|
| Cytokines | 1 | 2010 | 445 | 0.020 |
Why?
|
| Animals | 1 | 2010 | 10399 | 0.010 |
Why?
|